Get the Stockscreener App
13.09
0.77%
0.10
Pre-market:
13.46
0.37
+2.83%
Dbv Technologies Adr stock is traded at $13.09, with a volume of 774.68K.
It is up +0.77% in the last 24 hours and down -8.84% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$12.99
Open:
$13.09
24h Volume:
774.68K
Relative Volume:
4.56
Market Cap:
$525.35M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-12.47
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+1.43%
1M Performance:
-8.84%
6M Performance:
+60.81%
1Y Performance:
+219.27%
1-Day Range:
$12.96
$13.42
1-Week Range:
$12.75
$13.60
52-Week Range:
$2.74
$18.00
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
13.09 | 521.34M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | Guggenheim | Buy |
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at Guggenheim - Defense World
Check Out Netskope Inc (NTSK)’s Trade Data Rather Than the Analysts’ Views - Setenews
Taking on analysts’ expectations and winning: DBV Technologies ADR (DBVT) - Setenews
DBV Technologies stock initiated with Buy rating at Guggenheim - Investing.com
DEFSEC Technologies Inc (DFSC) expanding its growth trajectory ahead - Setenews
DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
European ADRs Slip As Gains And Losses Balance Out - Finimize
US Investors Show Renewed Interest In European ADRs - Finimize
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket - inkl
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - The Manila Times
DBV Technologies (NASDAQ: DBVT) marks last patient visit in 654-patient VITESSE study - Stock Titan
DBV Technologies Announces Last Patient Visit Completed in - GlobeNewswire
DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail
DBV technologies S.A. (ADR) (DBV1.SG) Balance Sheet - Yahoo! Finance Canada
Biotech Shines As UK And European ADRs See Mixed Results - Finimize
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
DBV (NASDAQ: DBVT) to join Guggenheim Healthcare Innovation Conf.; webcast, 90-day replay - Stock Titan
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - 24matins.uk
DBV Technologies (NASDAQ: DBVT) appoints Kevin Trapp to lead Viaskin Peanut commercialization - Stock Titan
European ADRs Show Mixed Moves In Active Sectors - Finimize
DBV Technologies Appoints Dr. Philina Lee to Board - The Globe and Mail
DBV Technologies Reports Q3 2025 Financial Results - MSN
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - The Manila Times
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting - The Manila Times
DBV Technologies (NASDAQ: DBVT) appoints Philina Lee to Board as independent director - Stock Titan
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - markets.businessinsider.com
Health Care And Telecom Drive European ADR Gains In The US - Finimize
European ADRs Mostly Flat As Gains And Losses Trade Off - Finimize
DBV Technologies Announces Sale of approximately $30 - GlobeNewswire
DBV Technologies (NASDAQ: DBVT) sells ~$30M in ADSs; dilution ~5.96% - Stock Titan
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '25 |
Sale |
2.22 |
464 |
1,030 |
109,649 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):